Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Low-Level Laser Therapy and Hyaluronic Acid After Free Gingival Graft

NCT07751211 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-06
Last updated
2026-10-07

Condition(s) studied

Gingival Recession, Mucogingival Surgery

Investigational drug(s) / intervention(s)

Topical Hyaluronic Acid GelLow-Level Laser TherapyFree Gingival Graft Surgery

Topical Hyaluronic Acid Gel: A 0.8% hyaluronic acid gel was applied directly to the recipient bed immediately before placement and stabilization of the free gingival graft. The gel was also applied topically to the palatal donor site immediately after surgery. Participants were prescribed the same gel and instructed to apply it to the palatal donor site three times daily for 14 days.

Low-Level Laser Therapy: Low-level laser therapy was administered to the palatal donor site and the recipient site using an 810-nm diode laser at 0.1 W in continuous-wave mode for 60 seconds. Laser applications were performed immediately after free gingival graft surgery and repeated on postoperative days 1, 3, 7, and 14.

Free Gingival Graft Surgery: A standardized free gingival graft was harvested from the palatal donor site and placed and stabilized at the recipient site in the mandibular anterior region to increase the width of keratinized gingiva.

Study summary

The goal of this randomized clinical trial was to learn whether low-level laser therapy or hyaluronic acid application improves healing after free gingival graft surgery in adults with insufficient keratinized gingival tissue in the mandibular lower teeth region.

The main questions it aimed to answer were:

* Do low-level laser therapy and hyaluronic acid application reduce shrinkage of the gingival graft?
* Do these treatments reduce postoperative pain and pain medication use and improve wound healing, clinical outcomes, appearance, and oral health-related quality of life?

Researchers compared three groups: free gingival graft surgery alone, free gingival graft surgery with low-level laser therapy and free gingival graft surgery with hyaluronic acid application.

Participants underwent free gingival graft surgery and were followed for six months. During follow-up, researchers measured graft size and shrinkage, periodontal clinical measurements, pain at the donor and recipient sites, pain medication use, wound healing, esthetic outcomes, and oral health-related quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Voluntary participation and provision of written informed consent * Systemically healthy adults aged 18 years or older * Non-smokers * No known drug allergies * Not pregnant or breastfeeding * Presence of Cairo RT1 or RT2 gingival recession in the mandibular anterior region * Keratinized tissue width of less than 2 mm at the planned grafting site * Plaque Score below 20% and Bleeding on Probing score below 20% * Vital teeth in the surgical area Exclusion Criteria: * Current use of medications that may interfere with wound healing or are contraindicated for surgical procedures * Pregnancy or breastfeeding * Ongoing orthodontic treatment in the affected region * History of previous periodontal surgery in the study area * Presence of active periodontal disease * Probing pocket depth greater than 3 mm in the involved teeth

Primary outcome measure(s)

  • Graft Shrinkage — Baseline and Months 1, 3, and 6
    Free gingival graft area was measured from standardized clinical photographs using ImageJ software. Graft shrinkage was calculated as the percentage reduction in graft area compared with the baseline postoperative graft area. Higher percentage values indicate greater graft shrinkage.

Trial sites (1)

FacilityCityRegionStatus
Altınbaş University Dental Hospital Istanbul Bakırköy Recruiting

More Altinbas University trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07751211 on ClinicalTrials.gov ↗ ← All trials in Turkey